文献速递临床试验与 GCP真实世界研究与卫生经济

LUMOS研究:数字远程预康复对比仅教育信息App的多中心随机对照试验方案

Study protocol for a multicenter prospective randomized-controlled trial to test a systematic remote and app-based prehabilitation program in comparison to education-only before major surgery: the LUMOS Study.
PubMed 文献 · Trials · 2026-09-10

LUMOS试验为多中心前瞻性随机对照研究,比较3至6周数字化预康复程序与仅接收数字化信息App的对照组,计划纳入382例拟行大手术患者,按诊断分层区组随机。主要终点为90天发病率从60%降至45%(Dindo-Clavien I-V级),并评估1年总生存、生活质量、住院时长、再入院率、依从性及医院费用等。

要点

  • 数字化远程预康复对比仅信息App,目标降低大手术90天发病率(60%至45%)。
  • 计划纳入382例,按诊断区组随机,干预时长3至6周。
  • 次要终点含1年生存、生活质量、住院时长、再入院、依从性及费用。

核心结论

  • LUMOS试验旨在评估数字化远程预康复程序相比仅提供信息App能否降低大手术患者围手术期发病率及费用。

研究设计与样本

  • 多中心前瞻性随机对照试验,比较3至6周数字化预康复干预程序与仅数字化信息App对照。
  • 计划纳入382例参与者,按诊断进行区组随机分配至干预组或对照组。

主要发现

  • 主要终点为90天发病率从60%降至45%(Dindo-Clavien I-V级)。
  • 次要终点包括1年总生存、生活质量、住院时长(含ICU、IMC和普通病房)、再入院率、依从性与项目坚持度、产品故障、警戒报告、6分钟步行试验改善至少20%及医院费用评估。

关键数值与推荐

  • 主要终点目标:90天发病率从60%降至45%(Dindo-Clavien I-V级)。
  • 6分钟步行试验改善至少20%为次要终点指标之一。

临床怎么用

  • 若试验证实有效,数字化远程预康复程序可整合至大手术术前管理路径以降低围手术期发病率。
  • 需关注干预依从性、产品安全性及费用影响,为临床推广提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have demonstrated significant benefits associated with prehabilitation prior to major surgery. However, digital solutions in this domain are currently lacking. Our previous study, the Protego Maxima trial, reported positively assessed usability, validity, and safety of a prehabilitation application. In this randomized-controlled multicenter study, we aim to ascertain whether a digital prehabilitation program can reduce perioperative morbidity and costs in patients undergoing major surgery. METHODS: The LUMOS trial is a multicenter prospective randomized-controlled trial comparing a 3-to-6-week interventional digital prehabilitation program with a digitized informational app, against a control group receiving only the informational application. The trial seeks to enroll 382 participants who will be block-randomized based on diagnosis into either the intervention or control group. The primary endpoint is the reduction of 90-day morbidity from 60 to 45% (Dindo-Clavien I-V). Secondary objectives include the 1-year overall survival, quality of life, length of hospital stay (including ICU, IMC, and general ward), readmission rates, compliance, and program adherence, product malfunction, vigilance reporting, improvement of the 6-min walking test by at least 20%, and hospital cost assessment. DISCUSSION: The LUMOS trial aims to evaluate the effectiveness of a digital prehabilitation program compared to an informational app only, prior to major surgery. The objective is to demonstrate the significant value of a digitized remote prehabilitation program in reducing perioperative morbidity, as well as addressing cost considerations. TRIAL REGISTRATION: Trial registered in the European Database on Medical Devices (EUDAMED) (CIV-24-02-046162) and German Clinical Trial Registry (DRKS00033612, 13.05.2024), DMIDS-Number: 00015083, https://drks.de/search/en/trial/DRKS00033612 . Goethe University Frankfurt: 024-1681-MDR/MPDG-zuständig multizentrisch, 06.05.2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sliwinski S, Stickl FJ, Faqar-Uz-Zaman SF, et al. Study protocol for a multicenter prospective randomized-controlled trial to test a systematic remote and app-based prehabilitation program in comparison to education-only before major surgery: the LUMOS Study. Trials. 2026. PMID: 42723102. doi:10.1186/s13063-026-09977-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。